We are excited to announce that Outbound Pharma has officially partnered with Oncoleader as part of our strategic initiative to enhance support for companies in the immuno-oncology sector. Oncoleader is a renowned leader in precision scientific communications, dedicated to bridging the gap between complex oncology research and impactful industry engagement.
The partnership between Outbound Pharma and Oncoleader is a big step for our clients. It offers a wide range of services that make business development smoother and improve communication in immuno-oncology. Combining Outbound Pharma's extensive business development expertise with Oncoleader’s deep scientific knowledge and competent communication strategies, we have created a powerful platform enabling immuno-oncology companies to connect effectively with the right audiences.
"Our partnership demonstrates our commitment to advancing innovation and excellence in the life sciences industry, especially in immuno-oncology. We look forward to working together to provide exceptional support, improved visibility, and strategic insights to drive our clients' growth and success," stated Claudio Rota, PhD, Founder and CEO at Outbound Pharma.
"We are very excited to partner with Outbound Pharma! At Oncoleader, we excel in delivering a compelling scientific narrative to the right people, in the right way. By combining our scientific communication expertise with Outbound Pharma's business acumen, we aim to spark fruitful collaborations that propel the field forward. As the immuno-oncology market evolves with advances in personalized medicine, our partnership is committed to enhancing visibility and strategic insights, empowering our clients to drive clinical and market success." says Dr. Jeff Martin, Founder of Oncoleader.
If you are looking for new opportunities in the IO space, please contact us.